Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Study sponsor: Emergent BioSolutions
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2008-12Actual
Enrollment · participants187Actual
Source updated2024-04-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.